Asset Details
Do you wish to reserve the book?
Rapamycin's lifespan effect is modulated by mito‐nuclear epistasis in Drosophila
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rapamycin's lifespan effect is modulated by mito‐nuclear epistasis in Drosophila
Do you wish to request the book?
Rapamycin's lifespan effect is modulated by mito‐nuclear epistasis in Drosophila
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rapamycin's lifespan effect is modulated by mito‐nuclear epistasis in Drosophila
2024
Overview
The macrolide drug rapamycin is a benchmark anti‐ageing drug, which robustly extends lifespan of diverse organisms. For any health intervention, it is paramount to establish whether benefits are distributed equitably among individuals and populations, and ideally to match intervention to recipients' needs. However, how responses to rapamycin vary is surprisingly understudied. Here we investigate how among‐population variation in both mitochondrial and nuclear genetics shapes rapamycin's effects on lifespan. We show that epistatic “mito‐nuclear” interactions, between mitochondria and nuclei, modulate the response to rapamycin treatment. Differences manifest as differential demographic effects of rapamycin, with altered age‐specific mortality rate. However, a fitness cost of rapamycin early in life does not show a correlated response, suggesting that mito‐nuclear epistasis can decouple costs and benefits of treatment. These findings suggest that a deeper understanding of how variation in mitochondrial and nuclear genomes shapes physiology may facilitate tailoring of anti‐ageing therapy to individual need. The burden of ill health in older populations has motivated a search for anti‐ageing drugs, such as rapamycin, but are putative benefits equal among variable populations? Genes vary on DNA contained both in the nucleus and contained in mitochondria. In flies, this study demonstrates the principle that combined genetic variation in nuclei and mitochondria can interactively shape rapamycin's beneficial effects, by altering when in the lifespan the drug affects mortality.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
